Navigation Links
Stemedica Completes Meeting with the FDA
Date:10/15/2009

Stemedica Cell Technologies, Inc. announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke. Based on a meeting October 13, 2009 with the FDA, Stemedica is planning to file an IND application in the first quarter of 2010.

San Diego, CA (PRWEB) October 15, 2009 -- Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke. Based on a meeting October 13, 2009 with the FDA, Stemedica is planning to file an IND application in the first quarter of 2010.

The proposed clinical trial will be a Phase I/II dose escalation and safety clinical trial using allogeneic mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke. The patient population will include individuals with a clinical diagnosis of chronic neurological or age-related neurodegenerative disease with significant functional or neurologic impairment that confines the subject to a wheelchair or requires the subject to have home nursing care or assistance with the general activities of daily living. The proposed trial will take place at medical centers within the United States.

"This is an important milestone for Stemedica," said
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
2. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
3. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
4. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
5. Stemedica Requests Pre-IND Meeting With FDA
6. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
7. Renowned Stem Cell Researcher Files Study Results With Stemedica
8. CIRM Completes Briefing Visit to Stemedica Cell Technologies
9. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Completes Meeting with the FDA
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... 13, 2011 PrimeraDx today announced that Jeff Liter ... Development.   "Jeff,s diverse background in all ... to the leadership team," Said Matt McManus, President and ... capabilities of the ICE Plex system in the ...
... a human gene mutation in a patient,s stem cells. ... 12 October, brings the possibility of patient-specific therapies closer ... researchers from the Wellcome Trust Sanger Institute and the ... both cirrhotic liver disease and lung emphysema. Using cutting-edge ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... Sequencing 200 Kit, which enables 200 base pair reads. The ... sequencer that can deliver millions of highly accurate long reads ... after our launch, the speed, simplicity and scalability of ...
Cached Biology Technology:PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2Clean correction of a patient's genetic mutation 2Clean correction of a patient's genetic mutation 3Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 2Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 3Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 4Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 5
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Microbes are everywhere thousands of species are in your mouth, ... in your mouth are mostly harmless as long as you ... gum disease a path into the blood stream. Microbes in ... country are also mostly harmless with some notable exceptions. ...
... from the National Cancer Centre Singapore, Duke-NUS Graduate Medical ... University (Thailand), have made a seminal breakthrough in understanding ... a rare but highly lethal form of liver cancer. ... Tan, Steve Rozen, Irinel Popescu and Vajaraphongsa Bhudhisawasdi, used ...
... the first conference of its 2013-2014 meeting season and ... "Advancing Vaccines in the Genomics Era" at the Windsor ... Grand Challenges in Global Health meeting for that program,s ... Symposia Global Health Series, supported by the Bill & ...
Cached Biology News:Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 2Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 3Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 4Singapore scientists expose molecular secrets of bile duct cancers from different countries 2Singapore scientists expose molecular secrets of bile duct cancers from different countries 3Keystone Symposia launches 2013-14 meeting series with first conference in Rio de Janeiro 2
... These plastic feeding tubes for rodent ... reduce the risk of perforation and trauma. ... hassle of cleaning and the risk of ... 20ga ...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 13(S)-HODE by GC- or ... linoleic acid with plant and mammalian lipoxygenases. It ... tumor cells to the endothelium at concentrations around ...
Biology Products: